You are here

Our science / Clinical Trials / Find a Trial / NCT00581620

Study Evaluating Prevenar Immunogenicity in High Risk Children

Back to Search Print Save as PDF Bookmark Trial

NCT00581620

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Conjugate Vaccine Vaccines
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-9 months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Children between 2 months to 9 years old.

- Children with HIV+; Sickle Cell disease; Neprotic symdrome; Chronic pulmonary disease

- No history of seizures

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Children between 2 months to 9 years old.

- Children with HIV+; Sickle Cell disease; Neprotic symdrome; Chronic pulmonary disease

- No history of seizures

NCT00581620
Pfizer
Completed
Study Evaluating Prevenar Immunogenicity in High Risk Children

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
NCT03313037
All Genders
60+
Years
Multiple Sites
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288
All Genders
0+
Years
Multiple Sites
Pneumococcal Disease
Study Evaluating Prevenar in High-Risk Children
NCT00234338
All Genders
2+
Years
Frankfurt,
Pneumococcal Meningitis
Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
NCT00227214
All Genders
0+
Years
Multiple Sites
Study Evaluating Prevenar Immunogenicity in High Risk Children
To Evaluate the Humoral Immune Response to a Conjugated Pneumococcus Vaccine 7-Valent (Prevenar®) in Children From High Risk Groups.
To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition. To evaluate tolerability of Prevenar® in that population.
This study will require 24 months to be completed. Each child will participate for a period of time according to age of the 1st dose of vaccination: infants up to 6 months of age will be evaluated for 5 months; infants between 7 to 11 months will be evaluated for 3 months; children between 12 months up to 9 years of age will be evaluate for 2 months
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Vaccines, Pneumococcal Conjugate Vaccine
Biological: pneumococcus conjugate vaccine
Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
  • Active Comparator: G1
    G1: HIV+
    Intervention: Biological: pneumococcus conjugate vaccine
  • Active Comparator: G2
    G2: Sicle Cell disease
    Intervention: Biological: pneumococcus conjugate vaccine
  • Active Comparator: G3
    G3: neprotic symdrome
    Intervention: Biological: pneumococcus conjugate vaccine
  • Active Comparator: G4
    G4: Chronic pulmonary disease
    Intervention: Biological: pneumococcus conjugate vaccine
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
160
September 2007
Not Provided

Inclusion Criteria:

  • Children between 2 months to 9 years old.
  • Children with HIV+; Sickle Cell disease; Neprotic symdrome; Chronic pulmonary disease
  • No history of seizures
Sexes Eligible for Study: All
2 Months to 9 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00581620
0887X-100974
No
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now